BrioHealth

What BrioHealth does

BrioHealth Technologies (operating under the legal entity CH Biomedical, Inc.) is a privately held medical device company founded in 2008 in Suzhou Industrial Park, China, with a wholly-owned US subsidiary (CH Biomedical USA, Inc. / BrioHealth Solutions) in Los Angeles, California. The company develops and commercializes fully magnetically levitated Left Ventricular Assist Devices (LVADs) for patients with end-stage heart failure, serving three clinical use cases: bridge to transplantation (BTT), bridge to recovery (BTR), and destination therapy (DT). Its core product, CH-VAD®, received NMPA marketing approval in November 2021 as China's first fully magnetically levitated LVAD with complete independent intellectual property rights and was commercially launched in December 2021. The next-generation BrioVAD™ System received FDA Investigational Device Exemption (IDE) approval in April 2024, with Medicare coverage secured in July 2024 and first US patient enrollment in the INNOVATE Trial at Emory University Hospital in November 2024.

The underlying technology centers on a centrifugal blood pump with full magnetic levitation (no mechanical or hydrodynamic bearing), a separated magnetic levitation and motor architecture, CFD-optimized flow paths (Nose Cone primary flow path and a 0.25 mm secondary flow gap), and a 3.3 mm ultra-thin percutaneous driveline. The R&D organization comprises 200+ members spanning medicine, physics, mechanical engineering, and electronics, with patents granted in China, the US, Europe, and Japan. Reported clinical outcomes include 93% survival at 1 and 2 years, 89% at 3 years, zero pump thrombosis, and lower driveline infection and stroke rates than INTERMACS benchmarks.

BrioHealth monetizes primarily through direct hospital sales of VAD hardware. In China, the device is sold to leading cardiovascular centers (Fuwai Hospital network, Beijing Anzhen Hospital, Wuhan Asia Heart Hospital, and others), reaching nearly 40 hospitals by 2023 and 50+ clinical centers by April 2024 with 350+ cumulative patients treated as of November 2024. In the US, distribution is currently channeled through the FDA-regulated INNOVATE clinical trial at sites including Emory University Hospital and University of Michigan Medical School, with Medicare reimbursement averaging approximately $220,000 per patient under MS-DRG 001. The company markets through academic conference engagement (ISHLT, ISMCS, ASAIO, Gordon Research Conference, EACTS MCS Summit) and peer-reviewed publications rather than traditional commercial channels, reflecting a clinically-led, regulatory-driven go-to-market model.

Name

BrioHealth

Legal name

BrioHealth Technologies, Inc.

Website

https://us.chbiomedical.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

BrioHealth Technologies develops fully magnetically levitated left ventricular assist devices (LVADs) for end-stage heart failure patients, commercially selling CH-VAD in China and advancing BrioVAD through the US INNOVATE Trial.

Ownership category

akta.pro rank

Product category

Ventricular Assist Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

akta.pro secondary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

Keywords

• Ventricular assist devices
• Left ventricular assist device
• Mechanical circulatory support
• Implantable cardiac devices
• Heart failure treatment

Headquarters

HQ city

Torrance

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. VAD Device Sales: Sale of CH-VAD and BrioVAD left ventricular assist devices to hospitals and healthcare facilities for treatment of end-stage heart failure patients. The company commercialized CH-VAD in December 2021 following NMPA approval and is pursuing US market entry through the INNOVATE Trial with Medicare reimbursement approval.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

BrioHealth Technologies develops and manufactures fully magnetically levitated left ventricular assist devices (LVADs) for patients with end-stage heart failure. Its commercial product CH-VAD® is sold to hospitals as an implantable mechanical circulatory support system, and its next-generation BrioVAD™ System is being introduced to the US market through the FDA-regulated INNOVATE clinical trial with Medicare reimbursement coverage.

Product overview

BrioHealth Technologies develops and commercializes fully magnetically levitated Left Ventricular Assist Devices (LVADs) for the treatment of end-stage heart failure. The product portfolio consists of two generations of devices: (1) CH-VAD®, the first domestically developed fully magnetically levitated LVAD with complete independent intellectual property rights approved by China's NMPA, featuring an implantable blood pump and external components; and (2) BrioVAD™ System, the next-generation device building on CH-VAD with enhanced portability of external wearable components. Both products are designed to partially or fully replace the heart's pumping function to maintain systemic circulation in patients with advanced heart failure.

Differentiator

Problem solved

Functional benefit

Brands

• CH-VAD: Implantable left ventricular assist system (LVAS) - a fully magnetically levitated ventricular assist device for treatment of end-stage heart failure. First domestically developed LVAD with complete independent intellectual property rights approved by NMPA in China.
• BrioVAD

Products and services

• CH-VAD® Left Ventricular Assist System CH-VAD® is an implantable left ventricular assist system (LVAS) composed of implantable components, external carrying components, peripheral components, and surgical tools. It uses a new-generation fully magnetically levitated centrifugal blood pump with a brushless DC motor, where the rotor is supported solely by magnetic levitation with zero mechanical friction. The device pumps blood from the left ventricle to the ascending aorta to partially or fully replace the heart's pumping function for end-stage heart failure patients, with applications in Bridge to Transplant (BTT), Bridge to Recovery (BTR), and Destination Therapy (DT).
• BrioVAD™ System BrioVAD™ System is the next-generation fully magnetically levitated left ventricular assist device developed based on CH-VAD. It uses the same implantable pump as CH-VAD but incorporates multiple technological innovations to achieve enhanced portability of external wearable components and overall system performance. The device is intended to provide long-term mechanical circulatory support for advanced heart failure patients and is being evaluated in the INNOVATE clinical trial in the United States with Medicare reimbursement under MS-DRG 001 averaging approximately $220,000 per patient.

Quantifiable outcome

• 1-year survival rate: 93%; 2-year: 93%; 3-year: 89% - exceeding international clinical trials and INTERMACS data
• +6 more outcomes

Named customers12 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered core.

• Fuwai Hospital (Chinese Academy of Medical Sciences)coreStrategic or Co-development Partner · 1 June 2017Academician Hu Shengshou led the first CH-VAD human implantation in June 2017 and served as Principal Investigator for clinical trials. Fuwai Hospital has become China's largest LVAD implantation center, conducting single-center studies with 50+ patients and presenting long-term follow-up results internationally at ISHLT 2024.
• Fuwai Hospital Animal Experiments CollaborationcoreStrategic or Co-development Partner · 1 January 2013In 2013, CH Biomedical teamed up with Fuwai Hospital under the Chinese Academy of Medical Sciences to conduct animal experiments prior to human clinical trials.
• Tsinghua UniversitycoreStrategic or Co-development Partner · 1 January 2009Academic partnership for VAD research and development as part of industry-academia-research collaboration. Supported by national key R&D programs and international cooperation projects funded by Ministry of Science and Technology since 2009.
• Zhejiang UniversitycoreStrategic or Co-development Partner · 1 January 2009Academic partnership for VAD research and development as part of industry-academia-research collaboration. Supported by national key R&D programs and international cooperation projects funded by Ministry of Science and Technology since 2009.
• Emory University HospitalcoreStrategic or Co-development PartnerEmory University Hospital served as the first US patient enrollment site for the INNOVATE Trial of BrioVAD system in November 2024. Dr. Mani Daneshmand leads the Emory Heart & Lung Transplantation and Mechanical Circulatory Support program.
• University of Michigan Medical SchoolcoreStrategic or Co-development PartnerDr. Francis D. Pagani serves as National Principal Investigator for the INNOVATE Trial. The Otto Gago, M.D., Professor of Cardiac Surgery leads the study evaluating BrioVAD system for advanced heart failure treatment.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Medtronic has historically been a major player in mechanical circulatory support (including the HVAD program) and operates broadly across cardiovascular devices. BrioHealth competes indirectly via the same LVAD indication set.
• Abiomed (Johnson & Johnson): Abiomed's Impella platform is the leading temporary mechanical circulatory support device; together with J&J's broader cardiovascular portfolio it competes for the same advanced heart failure patient pool as BrioHealth's durable LVAD.
• LivaNova: LivaNova produces heart-lung machines and other cardiac surgery equipment used during LVAD implantation and open-heart surgery, overlapping with the cardiovascular surgical ecosystem in which BrioHealth's VAD is deployed.
• Terumo Cardiovascular: Terumo provides ECMO and perfusion systems used alongside MCS in advanced heart failure care, serving overlapping hospital customers and surgical workflows as BrioHealth's CH-VAD.
• Getinge: Getinge (formerly Maquet) supplies cardiovascular surgery and perfusion equipment and has historical links to VAD programs, making it a comparable broader incumbent in the operating-room and MCS ecosystem.

Direct peers

• Abbott Laboratories: Abbott's HeartMate 3 is the dominant fully-implantable, FDA-approved LVAD for destination therapy in the US. BrioHealth's BrioVAD is explicitly positioned as a next-generation fully magnetically levitated LVAD to compete with HeartMate 3 in the INNOVATE Trial.
• Evaheart Inc: Evaheart develops a centrifugal-flow LVAD, making it one of the closest technology analogues to BrioHealth's fully magnetically levitated CH-VAD/BrioVAD platform and a direct competitor in advanced heart failure MCS.

Emerging players

• ReliantHeart: ReliantHeart is a smaller US LVAD developer focused on next-generation continuous-flow VADs with remote monitoring capabilities, making it a smaller but technically comparable competitor in the same implant category.
• CorWave: CorWave is developing a next-generation LVAD using a proprietary wave-membrane pump design, representing an emerging MCS competitor that intersects with BrioHealth's magnetic-levitation R&D path.
• Windmill Cardiovascular Systems: Windmill is developing next-generation pediatric and adult VADs using magnetically levitated rotor technology, making it a smaller emerging player in the same fully magnetic levitation category as BrioHealth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ch-biomedical-usa-inc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BrioHealth